Advances in antibiofilm strategies for medical implant-associated infections: emerging technologies and translational challenges Authors: Aditi Sharma, Bineypreet Kaur, Aditi Goyal, Purvi, Anu Priya Minhas Published: 2026 ABSTRACT Medical implants are instrumental for modern diagnosis, treatment, and management of disease. However, their increased usage has also raised concerns about implant associated infections. These infections are predominantly caused by microbial biofilms, conferring enhanced resistance to antimicrobial therapies, host immune responses, and environmental stresses, making infections difficult to eradicate. This review provided an updated overview of the evolving antibiofilm landscape for medical implants. It discusses major biofilm forming pathogens and mechanisms of biofilm development, followed by conventional and emerging approaches for biofilm prevention and eradication, including antifouling and antimicrobial coatings, quorum sensing inhibitors, hybrid or multifunctional or combination coatings, antimicrobial peptides, nanotechnology enabled platforms, photodynamic and photothermal therapies, immune targeting strategies, and smart coatings. The review further underscores the challenges associated with these antibiofilm strategies hindering clinical translation. Combating these challenges will play a crucial role in the future, improving antibiofilm therapies and patient outcomes in biofilm related medical implant infections. Introduction Medical implant devices are partly or wholly implanted inside the human body for diagnosis, therapy, and rehabilitation purposes, facilitating disease management, physiological assessment, and restoration of body functions. Catheters, dental, orthopaedic, cardiovascular, and urinary implants are commonly used medical devices (Cao et al., 2022). Dental implants, widely used to restore oral function and aesthetics (Neely and Maalhagh-Fard, 2017), cardiovascular implants, and central venous catheters are essential for medication delivery, hemodynamic monitoring, and cardiac support (Liang et al., 2021) and are vulnerable to bacterial colonization and biofilm establishment, leading to severe complications. The orthopaedic implant market is projected to grow from $46.5 billion to $78.5 billion by 2030 (Chen et al., 2023), highlighting increased reliance on these devices despite persistent infection risks. Majority of implant-associated infections are nosocomial infections and can range from localized to systemic (Haque et al., 2018; He et al., 2021; Kumar et al., 2024; Marina et al., 2022; Jamal et al., 2018). Clinically, polymicrobial biofilms are more abundant, complex, and resilient under dynamic flow than monomicrobial (Joshi et al., 2025), where interspecies quorum sensing (QS) complicates treatment, as targeting a specific pathogen may inadvertently boost another’s virulence (Lamin et al., 2022). Implant-associated factors, such as liquid flow rate through the device and the presence of host-derived adherent proteins, affect biofilm synthesis (Seneviratne, 2017). Increased implant use has led also raised device-associated infections, as indicated by bloodstream and catheter-related urinary tract infections, compromising patient recovery, increasing costs, and causing implant failure (Mishra et al., 2024; Yadav et al., 2020). The focus of this review is to highlight the evolving landscape of antibiofilm interventions managing biofilm-associated infections in medical implants. With this focus, the review discusses biofilm-forming pathogens, biofilm development mechanisms, strategies to prevent biofilm formation on medical implants, and clinical translation and regulatory considerations. Pathogens associated with biofilm formation Key pathogens associated with major implant niches include: Staphylococcus epidermidis and Staphylococcus aureus in cerebrospinal fluid shunts (Fux et al., 2006), S. aureus, Pseudomonas aeruginosa, and Pseudomonas acne on neurosurgical implants like neurostimulators (Conen et al., 2017), and P. acnes, Streptococcus, Lactobacillus, Bacillus, and Mycobacterium on breast implants (Pajkos et al., 2003). P. aeruginosa, S. aureus, S. epidermidis, Serratia spp., Escherichia coli, and Proteus spp. are reported to cling to contact lenses (Konduri et al., 2021). Multiple studies have reviewed non-implant-related infection and associated pathogen like dental plaque-associated Porphyromonas gingivalis, Bacteroides forsythus, and Actinobacillus actinomycetemcomitans (Zhao et al., 2023), vaginitis-linked Gardnerella vaginalis (Castro et al., 2015); otitis media-associated Haemophilus influenzae, Moraxella catarrhalis, and S. pneumoniae (Otsuka et al., 2013), infective endocarditis by S. aureus (Han and Poma, 2022), and necrotizing fasciitis by Acinetobacter baumannii (Grier et al., 2021), highlighting that biofilm pathogenesis extends beyond medical device colonization. Mechanism of biofilm formation Physicochemical and environmental stresses, including nutrient starvation, extreme pH, and temperature fluctuations, downregulates motility genes and upregulates adhesion genes triggering planktonic-to-biofilm transition. This transition induces extracellular polymeric substances production, restricting antibiotic penetration, promoting dormant cells, and enhancing long-term survival. Poor sanitation or septicemia can result in biofilm formation on medical implants following systemic inflammatory reaction. Biofilm development is a regulated, multistep process comprising initial adhesion, irreversible attachment, maturation, and dispersion (Figure S1) (Rather et al., 2021). The attachment of bacteria on the implant surface occurs via flagella, pili/fimbriae, adhesins, and non-fimbrial adhesins through physical forces (covalent, hydrophobic, and ionic) and forms permanent bonds with surfaces by secreting EPS consisting of extracellular DNA (eDNA), membrane-derived vesicles, polysaccharides, lipids, and water (Muhammad et al., 2020; Secchi et al., 2022; Campoccia et al 2021; Mugunthan et al., 2023). EPS provides stability, hydration, and protection, whereas eDNA supports biofilm initiation, integrity, and resistance (Sharma et al., 2023; Balducci et al., 2023). EPS accelerates intercellular signalling molecules synthesis like c-di-GMP (Frangleena and Suthindhiran, 2026), stimulating the production of pentasaccharide, alginate, and glucose-rich polysaccharide (Joo and Otto, 2012). Apart from EPS, biofilm maturation is driven by QS, which regulates biofilm formation. QS produces small signalling molecules called autoinducers, which coordinate bacterial group behaviour such as virulence and biofilm formation. Gram-positive bacteria secrete autoinducing peptides, while Gram-negative bacteria secrete N-acyl homoserine lactone as QS molecules (Ruhal and kataria, 2021; Sharma et al., 2023; Jiang et al., 2022). Slowly, as nutrients deplete, mature bacterial colonies disperse from the infection site by upregulating motility (flagella) genes to reattach to a new surface and downregulating surface attachment genes (Kaplan, 2010; Izabel-Shen et al., 2018). However, expression and regulation differ among the different bacterial species. Detachment occurs actively (via nutrient depletion or enzymes) or passively (via fluid shear forces) (Rumbaugh and Sauer, 2020), dispersing cells through abrasion, erosion, and sloughing. Strategies to mitigate biofilm formation Despite antibiotic treatment, biofilm persists during infections. Biofilm-associated microorganisms resist antimicrobial agents and tolerate environmental stress, making conventional treatments less effective. All these factors drive development of thin-film coatings for medical implant surfaces, with research focusing on innovative strategies to prevent biofilm formation or disrupt established biofilms. This review covers conventional anti-biofilm approaches (i.e., antibiofilm and antifouling agents, QS inhibitors (QSI), and hybrid or combination or multifunctional antimicrobial coatings) and Emerging approaches, such as antimicrobial peptides (AMPs), nanotechnology-based, photodynamic and photothermal therapies, bioelectric and acoustic strategies, and smart coatings as summarized in Table 1. Table 1Summary of advancement in antibiofilm strategies in mitigating implant associated infections.CategoryStrategyMechanism of actionReferencesConventional techniquesAnti biofilm compoundsAntifouling coatingsInhibit microbial colonization, inhibit biofilm formation, lower microbial adhesion, reduce biofilm biomass by contact- based killing or antimicrobial release.Campoccia et al. (2013), Su et al. (2025), Durand et al. (2022), Mondal et al. (2021), Saverina et al. (2023), Chen (2022), Li et al. (2024), Wu et al. (2018), Paxton et al. (2021), Rostami et al. (2021), Zhang et al. (2026), Su et al. (2025).Inhibition of quorum sensing(QS inhibition coatings)Regulate biofilm formation by coordinating with global gene expression, disrupt signalling pathways, using natural compounds like polyphenols, flavonoids etc. and synthetic compounds like β-lactams, benzothiazole derivatives etc. which prevent biofilm maturation and persistence.Juszczuk-Kubiak (2024), Mishra et al. (2024), Naga et al. (2024), Wang Y. et al. (2024), Luo et al. (2017), Wang Y. et al. (2024), Khadraoui et al. (2024), Naga et al. (2024), Naga et al. (2024)Hybrid and multifunctional coatings and combination coatingsGenerate ROS, inducing oxidative stress with bioelectric and acoustic strategies, damage of cellular components by disrupting membrane integrity.Antimicrobial activity with bioactive elementsIncrease antibacterial activity, improved penetration into biofilm formation, reduce antibiotic resistance, Interrupt biofilms and boosts treatment efficacySharma et al. (2023), Puspasari et al. (2022), Monika et al. (2025), Yan et al. (2018), Raphel et al. (2016), Mas-Moruno et al. (2018), Wang X. et al. (2025), Wang Y. et al. (2024), Lv et al. (2015), Charria-Girón et al. (2024), Ghosh (2024), Deng et al. (2022), Kaplan et al. (2024), Xinnan et al. (2018), Liu et al. (2026), Fan et al. (2017), Zou et al. (2022), Lee and Kim (2023), Tamimi et al. (2024), Odeh et al. (2025)Novel ApproachesNovel Antimicrobial peptides coatingsDisrupts microbial membranes, prevents fungal and bacterial biofilm formation provide localized, contact-based activity, limiting early biofilm formation with sustained drug release when immobalized.Alzahrani et al. (2022), Hashemi et al. (2017), Freitas et al. (2022), Sun et al. (2018), Kazemzadeh-Narbat et al. (2020), Khanda et al. (2025), Riool et al. (2017)Nanotechnology based coatingsReduction in bacterial growth with phage/metal encapsulations for safe penetration, targeting biofilm associated pathogens while still less cytotoxic effects.Xu et al. (2019), Yi et al. (2020), Singh et al. (2018), Mayorga Ramos et al. (2024), Panthi et al. (2024), Chu et al. (2024), Jayaramudu et al. (2025), Behzad et al. (2020), Kungwani et al. (2024), Pathak et al. (2026), Harun-Ur-Rashid et al. (2025), Panthi et al. (2024), Bouiti et al. (2024)Photodynamic therapyCombination (PDT + PTT)Photo thermal and chemical based antibacterial effect, producing localized heat, ROS production and ion release targeting both planktonic and biofilm associated bacteria.D’Agostino et al. (2016), Fan et al. (2017), Jia et al. (2019), He et al. (2022), Wang X. et al. (2024), Wang T. et al. (2025), Koç et al. (2025)Smart coatingsTargeting immune systemSuppress nonspecific protein adsorption. Penetrate mucus barrier, degrade biofilms, generate ROS, Modulate macrophage polarization and immune signalling, Local release of gasotransmitter provides antibacterial efficacy and immune homeostasis exogenous stimulus-responsive therapiesGallo et al. (2014), Linklater et al. (2020), Kim and Oliver (2023), Su et al. (2022), Xie et al. (2025), Su et al. (2024), Xiu et al. (2023), Wang Z. et al. (2025), Guo et al. (2020), Yang et al. (2024a), Xu et al. (2024), Castanheira and Kubes (2018), Cappelli and Shah (2020), Li et al. (2023), Morandini et al. (2023)Stimulus-responsive coatingintegrated sensor systems combining antimicrobials at low dose with weak electrical and/or ultrasound waves for real-time detection and monitoring of infections, detects physiological cues- such as pH and temperature shifts, provide “on-demand” release antimicrobial agents only when pathogens are present for infection control.Joshi et al. (2023), Wang Y. et al. (2024), Xia et al. (2024), Yang et al. (2024a), Albalawi (2024), Wang X. et al. (2024), Pereira (2026), Pal (2024), Hu et al. (2022), Yu et al. (2023) Summary of advancement in antibiofilm strategies in mitigating implant associated infections. Conventional approaches Antifouling, antimicrobial, anti-biofilm coating, and anti-adhesive surface modifications Since bacterial adhesion and biofilm initiation are influenced by physicochemical surface properties, modifying these properties has become an important strategy to reduce microbial colonization and implant-associated infections (Campoccia et al., 2013; Su et al., 2025). The antimicrobial coatings can eliminate bacteria through contact killing or microbe inactivation, using agents such as metal nanoparticles, polycations and antibiotics (Durand et al., 2022; Saverina et al., 2023). In contrast, antifouling coatings are passive preventive strategies deterring microbes’ settlement on the surface. These include, hydrophilic polymers (polyvinyl alcohol, PVA), poly (2-hydroxyethyl methacrylate) (PHEMA), dextran, and zwitterionic materials reduce protein adsorption and maintain a hydrated interface, minimizing microbial colonization without exerting bactericidal effects (Chen, 2022). Although antifouling strategies prevent initial adhesion, maintaining stable material surface properties is a must, as reviewed in detail by (Li et al., 2024). The anti-adhesive surface modifications incorporating nanoscale topographies, including nanopillars and nanospikes fabricated from titanium dioxide, graphene oxide, nanoporous polymers, and diamond nanostructures, prevent bacterial adhesion through contact-mediated bactericidal activity. These nanostructures mechanically stretch, deform, or puncture bacterial membranes, causing irreversible membrane disruption and cell death (Wu et al., 2018; Zhang et al., 2024). However, their functionality is limited by challenges such as scalability, cost, and performance under physiological conditions (Su et al., 2025). QS inhibition coatings QS signalling pathways regulate the expression of genes responsible for virulence, EPS, stress response, and biofilm formation via autoinducers (Mishra et al., 2024; Juszczuk-Kubiak, 2024). Plant metabolites such as polyphenols, flavonoids, phenolics, garlic extract, tea polyphenols, and hamamelitannin are natural non-coating QSIs as reviewed in (Naga et al., 2024). Of these, berberine reports to reduce S. aureus adhesion, suppress biofilm development, interfere with QS and lessen the chance of developing antimicrobial resistance (Wang X. et al., 2024). Baicalin, a natural low-toxicity antibiofilm agent, enhances antibiotic efficacy against resistant strains (Wang X. et al., 2024b; Luo et al., 2017). Myrtus communis phenolic leaf extract exhibits potent quorum-sensing inhibition, suppressing biofilm formation, swarming, pyocyanin, and protease in P. aeruginosa by downregulating QS regulators. In this active extract, among phenolics, 3,5-di-O-galloylquinic acid exhibited strongest in silico binding to Chromobacterium violaceum CviR receptor (Khadraoui et al., 2024). Antibiofilm strategies eradicate established biofilms using chemical, biological, or physical agents. Synthetic QSIs disrupt autoinducer signaling and biofilm maturation (Naga et al., 2024), whereas surface-functionalized coatings known as coating based QSIs employ DNase I, dispersin B, or lysozyme for degrading the extracellular matrix, promoting biofilm dispersal and enhancing antimicrobial efficacy. Although QSIs reduce bacterial pathogenicity by suppressing QS-regulated virulence factors and exhibit broader applicability, including healthcare, their application is limited by potential resistance development, toxicity, and insufficient clinical validation in humans (Naga et al., 2024). Hybrid, multifunctional, or combination coatings The above-mentioned strategies, though effective in vitro against monomicrobial infections, pose limitations when targeting polymicrobial biofilms (Bayramov and Neff, 2016). Many S. epidermidis biofilms resist vancomycin, despite planktonic form is sensitive (Sharma et al., 2023). Hybrid and multifunctional coatings are often interchangeable; hybrid emphasizes the composition of the coating, while multifunctional focuses on functions. ZnO-based hybrid coatings integrated with polymer matrix exhibit antimicrobial and antibiofilm activity via generating reactive oxygen species (ROS) and releasing Zn2+ following altered metabolism and membrane integrity, leading to structural damage (Puspasari et al., 2022; Monika et al., 2025; Gocheva et al., 2026). The porous polyetheretherketone hybrid coating embedded with gentamicin and AgNPs (within a silk fibroin matrix) exhibits antibacterial activity via membrane permeabilization, ROS production, DNA damage, and biofilm inhibition compared to sole agent coatings (Yan et al., 2018). Multifunctional orthopaedic coatings combat infection and promote osseointegration by combining antimicrobial and bioactive agents (Raphel et al., 2016). Micro- and nanoscale engineering favours osteoblast over bacterial adhesion (Mas-Moruno et al., 2018). Bioinspired urushiol polymer is durable, biocompatible, and exhibits antibacterial activity (Wang T. et al., 2025). Combination therapy augments efficacy by improving penetration and reducing minimum inhibitory concentration through synergistic effects. This includes cumin aldehyde-tobramycin-based enhanced ROS production and biofilm disruption (Wang X. et al., 2024b), and berberine-vancomycin reduces C. difficile recurrence (Lv et al., 2015). Further, bacteriophages with vancomycin (Charria-Girón et al., 2024), colistin-based combinations (Wang X. et al., 2024b; Ghosh, 2024), and enzymes like DNase or dispersin B (Deng et al., 2022; Kaplan et al., 2024), show improved biofilm eradication and limit resistance development. Zwitterionic and poly(ethylene glycol) methacrylate, (PEGMA)-Ti6Al4V coated implant surfaces significantly limit attachment of S. epidermidis and S. mutans while maintaining biocompatibility with implants (Xinnan et al., 2018). Dopamine-altered polysaccharide sulfate-coated silver-graphene hybrids exhibit a synergistic effect by producing localized heat under near-infrared radiation (NIR) with enhanced Ag+ release and antimicrobial effect (Fan et al., 2017). A triple-defense coating of hyaluronic acid, quaternized chitosan, and acylase exhibits anti-adhesion, bactericidal, and quorum-quenching properties (Zou et al., 2022). Bioelectric effect (BE)-integrated toothbrushes achieve dental implant inflammation by reducing plaque (67%) and bleeding (59%) (Lee, 2023) while achieving ~99% reduction in bacterial biofilms on knee arthroplasty implants (Tamimi et al., 2024). A combination of direct electrical current with chlorhexidine removed >95% vitality of multispecies biofilm from titanium implant compared to chlorhexidine alone (Odeh et al., 2025). The challenges associated with coatings are clinical translation, toxicity associated with metal nanoparticles and ROS, external stimuli dependence, scalability, production cost, sophisticated material designs, and long-term stability. Therefore, it requires optimization and extensive in vivo validation for clinical applications. Emerging approaches Antimicrobial peptides (AMPs) coatings Antimicrobial peptides (AMPs) are surface-active molecules with broad-spectrum activity against implant infections by disrupting microbial membranes, impeding bacterial adhesion, and targeting multidrug resistance. IDR-1018 inhibits biofilms via suppressing (p)ppGpp, while LF-11 reduces biofilm formation and motility (Alzahrani et al., 2022). In preclinical tests, ceragenin CSA-131 prevents fungal and bacterial biofilm formation on endotracheal tubes and exhibits protection against microbial colonization (Hashemi et al., 2017). Self-assembly, polymer conjugation, and nanoparticle integration enhance durability and efficacy (Freitas et al., 2022) (Sun et al., 2018). On surface immobilization, AMPs provide localized, contact-based activity, limiting biofilm formation with sustained drug release (Kazemzadeh-Narbat et al., 2020; Khanda et al., 2025). However, clinical use is limited by scalability challenges, high cost, and regulatory constraints (Riool et al., 2017). Nanotechnology-based coatings Chloramphenicol-loaded gelatin nanoparticles target biofilms and are effective in reducing bacterial growth by 55.6 and 63.2% in 4 and 8 h, promoting wound healing with minimized cytotoxicity (Xu et al., 2019; Yi et al., 2020). Surface modification can further lower cytotoxicity (Singh et al., 2018). Bacteriophages encapsulated with chitosan or metallic nanoparticles exhibit antibacterial activity and eradicate biofilms while stabilizing and protecting phages, Mayorga Ramos et al. (2024) and Panthi et al. (2024) while TiO₂ nanorods and chitosan-capped TiO₂ hybrids enhance photocatalytic antibacterial activity against E. coli and S. aureus (Chu et al., 2024; Jayaramudu et al., 2025). Metallic nanoparticles (such as silver, gold, zink oxide (ZnO)) can safely penetrate and target pathogens associated with antibiotic-resistant biofilm matrices with low mammalian cytotoxicity (Behzad et al., 2020; Pathak et al., 2026). Silver-polymer nanocomposites with liposomes show improved antimicrobial efficacy, stability, and suitability (Panthi et al., 2024; Harun-Ur-Rashid et al., 2025). Bouiti et al. (2024) introduced nano-hybrid platforms that integrate nanoscale constituents-such as nanoparticles, nanocomposites, and nanotubes-into polymer matrices to enhance mechanical, optical, and thermal properties while providing advanced self-healing and responsive functionalities. However, it requires standardized safety assessments of such coatings for regulatory approval. Photodynamic and photothermal therapy Antimicrobial photodynamic therapy (PDT) is a minimally invasive technology employed to eradicate implant-associated multidrug-resistant biofilms. Triangular silver nanoplates designed on glass surfaces exhibit both photothermal and chemical-based antibacterial actions, facilitating the removal of adherent E. coli and S. aureus biofilms (D’Agostino et al., 2016). The synergistic systems of photothermal agents (PTAs) and antimicrobial agents, like dopamine-altered polysaccharide sulfate-coated silver-graphene hybrids, produce localized heat under NIR, which can enhance Ag+ release and microbial death (Fan et al., 2017). PDT represented by cellulose-based coating conjugated with protoporphyrin IX (PpIX) and quaternary ammonium salts significantly upregulate the production of ROS against both forms of bacteria (planktonic and deposited on surfaces) (Jia et al., 2019). PDA/AgNP engineered heterostructures on sulfonated PEEK surface enhance metal ion release with photothermal effects, with efficient antibiofilm activity (He et al., 2022). Wang X. et al. (2024) demonstrate a combination approach involving PDT, photothermal therapy (PTT), and chemodynamic therapy (CDT) to treat cervical tumors (Wang Y. et al., 2024). Wang X. et al. (2025) developed a red-light-activated metal-organic framework (Ce6@ZIF-8-PDA/UBI) employing polydopamine and ubiquicidine peptide, targeting bacteria by penetrating deep into oral biofilm. It helps to achieve 14-day wound healing, eradicates S. aureus, E. coli, F. nucleatum, P. gingivalis, and eliminates S. aureus biofilms from titanium implants in a mouse model (Wang X. et al., 2025). In another study, both PDT and PTT generated ROS and eradicated biofilms employing heat (Koç et al., 2025). While such systems demonstrate synergistic and targeted destruction of resistant biofilms (utilizing minimally invasive, advanced penetration techniques), their clinical viability is limited by tissue depth, external irradiation, and unmapped host immune responses, with only animal models available rather than human trials. Coatings targeting immune system Impaired host immunity promotes biofilm survival. Subnanometer implant coating suppresses nonspecific protein adsorption and lowers macrophages/neutrophils, reducing inflammation and promoting tissue regeneration (Gallo et al., 2014; Linklater et al., 2020). Manipulating macrophages restores innate immunity via lncRNA-Cox2 (long non-coding RNA that regulates the cyclooxygenase-2 gene) pathways (Kim and Oliver, 2023); precise regulation is essential to minimize inflammation and impaired tissue integration. Gasotransmitters like hydrogen sulfide and carbon monoxide (CO) exhibit antibacterial and M2-mediated immune homeostasis activities that repair tissue (Su et al., 2022). Metal ion-release coatings modulate immune signals and macrophage polarization: Ag2+ and Cu2+ favour M2 over M1 macrophages while Zn2+ enhances neutrophils and macrophages, suppressing cytokines (Yang et al., 2024a; Zhao et al., 2023). Cryoprotectant CO mitigates inflammation by lowering M1/TNF-/ROS and elevating IL-10 (Wu et al., 2025; Zhou et al., 2024). Probiotic-nanomaterial hybrids (e.g., LP@FeTA/CuPt) combat H. pylori by penetrating mucus, generating ROS, preventing biofilms, regulating microbiota, and restoring immunity (Zhang et al., 2026). Depending on exogenous stimuli, stimulus therapies are: Photo Stimulus: With non-invasive PDT and PTT activation, these treatments can destroy targeted cells or pathogens by generating cytotoxic ROS and localized heat, respectively. R-AuSTP-Be platform eradicate biofilms, drive M1-to-M2 polarization, and relieve inflammation (Xie et al., 2025). Photo Stimulus: With non-invasive PDT and PTT activation, these treatments can destroy targeted cells or pathogens by generating cytotoxic ROS and localized heat, respectively. R-AuSTP-Be platform eradicate biofilms, drive M1-to-M2 polarization, and relieve inflammation (Xie et al., 2025). Ultrasound Stimulus: MnP nanoparticles activated by acoustic energy can trigger cGAS-STING for M1/Th17 responses (Su et al., 2024), while microbubbles improve phagocytosis and M1 polarization (Xiu et al., 2023). Ultrasound Stimulus: MnP nanoparticles activated by acoustic energy can trigger cGAS-STING for M1/Th17 responses (Su et al., 2024), while microbubbles improve phagocytosis and M1 polarization (Xiu et al., 2023). Chemodynamic Therapy (CDT): Radical-generating SP-PFe activates M2 polarization (Wang Z. et al., 2025), whereas CuFe5O8 nanocubes drive M1 polarization and reverse immunosuppression (Guo et al., 2020). Chemodynamic Therapy (CDT): Radical-generating SP-PFe activates M2 polarization (Wang Z. et al., 2025), whereas CuFe5O8 nanocubes drive M1 polarization and reverse immunosuppression (Guo et al., 2020). Magnetic Hyperthermia: Alternating fields with Mg implants reduce inflammation and promote repair via H+ depletion (Yang et al., 2024b) while magnetic nanospheres promote M1 polarization and phagocytise dormant bacteria (Xu et al., 2024). Magnetic Hyperthermia: Alternating fields with Mg implants reduce inflammation and promote repair via H+ depletion (Yang et al., 2024b) while magnetic nanospheres promote M1 polarization and phagocytise dormant bacteria (Xu et al., 2024). Immune modulation risks implant tissue damage via sustained release of cytokines, ROS, Neutrophil Extracellular Traps, and enzymes (Cappelli and Shah, 2020; Li et al., 2023). Smart coatings Smart stimulus-responsive coatings represent a transformative shift in orthopaedic implants as self-regulating systems that dynamically manage the implant environment. By detecting physiological cues- such as pH and temperature shifts- these materials provide “on-demand” infection control, releasing antimicrobial agents when pathogens are present. During healthy conditions, they switch functionality to promote osseointegration by facilitating bone cell attachment. By balancing dual roles, these smart coatings optimize the competition between infection prevention and regenerative healing to ensure successful implant integration (Joshi et al., 2023). Smart coatings are integrated sensor systems combining antimicrobials at low doses with weak electrical and/or ultrasound waves for real-time detection and monitoring of infections (Wang et al., 2024). Ultrasound-mediated sonodynamic therapy exhibits antibacterial activity against resistant microbes (Xia et al., 2024) while activated piezoelectric nanomaterials exhibit antibacterial activity against E. coli and S. aureus by producing electric signals (Yang et al., 2024). Acoustic methods are being explored for non-invasive, real-time biofilm characterization despite challenges (Albalawi, 2024). Recent stimuli-responsive smart coatings release antimicrobial on-demand, such as pH-responsive titanium coatings, that sustain antibiotic delivery with tissue integration (Pereira, 2026). Pereira (2026) integrated a pH-sensitive poly (methacrylic acid) (PMAA) film on a layer-by-layer (LbL) platform with tetracycline-β-cyclodextrin (TCβCD) complex for titanium coating. This demonstrates controlled, pH-dependent drug release, minimizing burst effects at neutral pH while accelerating release in acidic, inflammatory environments enhancing antimicrobial efficacy and promoting favourable soft-tissue integration and collagen maturation without inducing cytotoxicity (Pereira, 2026). Further electrochemical sensing integrated with microfluidics is a cost-effective alternative for low-power bacterial detection. Pal (2024) developed a scalable, cost-effective spray-coating method using a Copper Oxide nanoparticles/TiO₂ hybrid coating on polypropylene surfaces with dual mechanisms of action. The contact killing antimicrobial activity (from CuO nanoparticles) and super hydrophobicity-driven anti-biofouling (from the TiO₂ surface texturing), together achieve a > 6-log reduction (R ≥ 6) in bacterial load for both E. coli and S. aureus while preventing biofilm formation (Pal, 2024). A titanium-based orthopaedic implant was functionalized with a pH- and NIR-responsive mesoporous polydopamine nanoparticles (MPDA)-luteolin@calcium phosphate coating containing mesoporous polydopamine, the QSI luteolin, and a calcium phosphate shell. Due to acidic biofilm conditions, luteolin is released from the coating to inhibit QS-regulated biofilm formation, while the release of Ca2+ and PO₄3− boosts osseointegration. NIR-triggered photothermal activity of MPDA causes bacterial membrane disruption, resulting in protein leakage and ATP depletion. However, this approach requires NIR irradiation, which may damage surrounding tissues, and potential cytotoxicity associated with high concentrations of QSI (Hu et al., 2022). Similarly, a modified titanium implant surface called Ti-polydopamine @S-nitrosoglutathione-osteogenic growth peptide was coated to destroy methicillin-resistant S. aureus biofilm, promoting bone healing and osseointegration (Yu et al., 2023). These coatings are effective, yet their transition to large-scale production is constrained by complex synthesis requirements and microcracking of sol–gel process at higher thicknesses. Clinical regulations and translational considerations Clinical translation barriers to antibiofilm coatings include toxicity, high costs, regulatory hurdles, and limited biofilm penetration efficacy. Additional challenges involve antimicrobial peptide degradation (Mahlapuu et al., 2016) and the requirement of active, long-lasting, and biocompatible nanomaterials or coatings capable of surviving complex in vivo environments (Campoccia et al., 2013; Liu et al., 2026). Persistent periprosthetic joint infections demand translatable non-antibiotic antibiofilm strategies (Margaryan et al., 2025). Personalized high-throughput screening of pathogen-specific coatings could improve clinical translation (Ghezzi et al., 2023), similarly to how sodium cocoamphoacetate enhances metronidazole against bacterial vaginosis biofilms better than antibiotics alone (Gottschick et al., 2016) and a combination of electrical current with chlorhexidine in dental implants (Odeh et al., 2025). Translation of nanoparticle-based coatings is limited by cytotoxicity, stability, and delivery issues. Scalability remains difficult because minor particle variations alter efficacy (Kumarage et al., 2026), and excessive immune modulation risks bystander tissue damage or autoimmunity (Van Roy and Kielian, 2025). Consequently, the U. S. Food and Drug Administration and European Medicines Agency approvals require comprehensive pre- and post-market data alongside standardized ISO testing (13,485, 10,993, 14,971) to ensure safety and efficacy (Singh et al., 2026). Conclusion In conclusion, implant-associated biofilm infections remain a major challenge due to the complex and adaptive nature of biofilms, conferring them protection against both host and environmental factors. This review highlights the expanding repertoire of antibiofilm strategies, ranging from conventional to smart responsive coatings. Despite promising preclinical outcomes, the clinical translation of these technologies is constrained by challenges of biocompatibility, cytotoxicity, long-term stability, scalability, and regulatory approval. Furthermore, as implant-associated infections are frequently polymicrobial, future studies must validate emerging strategies using clinically relevant multispecies biofilm models. Future efforts should prioritize clinically relevant polymicrobial models, standardized evaluation methods, and integrated, personalized antibiofilm platforms for improving implant safety, reducing infection rates, and enhancing patient outcomes.